Pan-NR agonists, such as RGX-202, activate PPARα, PPARγ, and PPARδ, leading to improvements in lipid metabolism, insulin sensitivity, and fatty acid oxidation, with potential applications for metabolic syndrome, dyslipidemia, and CVD [247]. Here, INS is linked to metabolic syndrome.